《CardinalHealth：2022年生物仿制药报告（英文版）（36页）.pdf》由会员分享，可在线阅读，更多相关《CardinalHealth：2022年生物仿制药报告（英文版）（36页）.pdf（36页珍藏版）》请在三个皮匠报告上搜索。

1、2022 Biosimilars Report:The U.S.Journey and Path Ahead23Welcome to our 2022 Biosimilars Report:The U.S.Journey and Path AheadCardinal Health is fortunate to sit at the crossroads of the United States(U.S.)healthcare system,engaging with stakeholders from across the industry including healthcare prov

2、iders,health systems,pharmaceutical and medical product manufacturers,pharmacists,payers and policy makers to support the delivery of essential care to the most important stakeholder patients.This vantage point has given us a unique perspective on the important role of biosimilars in the U.S.healthc

3、are landscape and the potential benefits they may deliver to patients and the healthcare system at large.Since the first biosimilar was approved in the U.S.in 2015,we have taken an active role in supporting the use of these products not only by distributing them to healthcare providers and working w

4、ith manufacturers to bring new biosimilars to market,but also through extensive research and educational initiatives designed to build a better understanding of how biosimilars may contribute to high-quality,lower-cost care.In this,our first-ever Biosimilars Report:The U.S.Journey and Path Ahead,we

5、have aspired to bring together the latest industry data on utilization and payer coverage with our own research and perspectives from leading experts on where biosimilar adoption stands today in the U.S.,and what we can expect in 2022 and beyond.We are pleased to include views from our internal expe

6、rts and top physicians in key therapeutic areas where biosimilars are making an impact.The report also features results from our research with healthcare providers,which includes surveys with more than 320 oncologists,100 rheumatologists,100 retina specialists,50 endocrinologists and primary care ph